Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hong Kong
Biotech
Why US biotech Axiom is starting its IPO journey in Hong Kong
The move follows a phase 1 data drop on Axiom's lead stem cell therapy in the treatment of two fatal newborn neurological diseases.
Marissa Russo
Jul 21, 2026 7:02am
Insilico Medicine aims to generate nearly $300M in Hong Kong IPO
Dec 18, 2025 11:17am
Cornerstone secures $200M to take its surgical robot global
Nov 18, 2025 9:45am
I-Mab unveils new name, strategy, asset and Hong Kong IPO plans
Oct 17, 2025 10:45am
Leads Biolabs hits Hong Kong stock exchange in $189M IPO
Jul 25, 2025 10:59am
BioNTech backing powers DualityBio toward $200M Hong Kong IPO
Apr 7, 2025 8:21am
